Clinical trial
Randomized Phase II Study of Docetaxel/Gemcitabine vs. Docetaxel/Cisplatin in Metastatic or Locoregionally Advanced Pancreatic Carcinoma
NCT00004884 is registered in ClinicalTrials.gov with European Organisation for Research and Treatment of Cancer - EORTC as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Randomized Phase II Study of Docetaxel/Gemcitabine vs. Docetaxel/Cisplatin in Metastatic or Locoregionally Advanced Pancreatic Carcinoma
- Lead sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- July 31, 1999
- Completion date
- Not reported
- Enrollment
- 96 (actual)
- Sites
- 19
Conditions
As the registry lists them; a condition with its own page is linked.
pancreatic cancer